Dutasteride could provide a beneficial adjunct to active surveillance for men with low-risk prostate cancer. ..
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial
The Altmetic score is one measure of the quality and quantity of online attention that this article has received. You can read about how Altmetic scores are calculated here.
This article scored 39.50
Compared to all articles in The Lancet So far Altmetric has tracked 6,142 articles from this journal. They typically receive a lot more attention than average, with a mean score of 10.7 vs the global average of 3.5. This article has done particularly well, scoring higher than 94% of its peers. |
In the
94%ile |
Ranks346th
|
All articles of a similar age Older articles will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this score to the 120,659 tracked articles that were published within six weeks on either side of this one in any journal. This article has done particularly well, scoring higher than 98% of its contemporaries. |
In the
98%ile |
Other articles of a similar age in The Lancet We're also able to compare this article to 539 articles from the same journal and published within six weeks on either side of this one. This article has done well, scoring higher than 87% of its contemporaries. |
In the
87%ile |
Ranks69th
|
All articles More generally, Altmetric has tracked 1,236,786 articles across all journals so far. Compared to these this article has done particularly well and is in the 99th percentile: it's in the top 5% of all articles ever tracked by Altmetric. |
In the
99%ile |
So far Altmetric has seen 0 videos from 0 accounts.
So far Altmetric has seen 1 blog post.
Tweet JAMA 21 Mar 2012 Vol 307 1161 When in Japan, do not attempt to drop down dead. In 800 fire stations around the I ..
So far Altmetric has seen 0 group forum posts from 0 accounts.
Geographical breakdown
|
Tweeter demographics
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 5% |
| Scientists | 24 | 66% |
| Practitioners (doctors, other healthcare professionals) | 9 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
So far Altmetric has seen 1 public wall post.
[Articles] Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial
So far Altmetric has seen 0 Google+ posts from 0 accounts.
So far Altmetric has seen 1 review.
F1000Prime
So far Altmetric has seen 1 story.
The New York Times
Fewer than 10 percent of the 100,000 men each year who get a diagnosis of early-stage prostate cancer and have the option ..
So far Altmetric has seen 0 threads from 0 accounts.
So far Altmetric has seen 36 tweets from 27 accounts with an upper bound of 53,099 combined followers.
Dutasteride in localised prostate cancer management http://t.co/82s5BW7c
[Articles] Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, pla... http://t.co/9vzCvLGQ #cancer
@ThePeeDoc - #Dutasteride (#Avodart) Slows progress of Prostate Cancer - REDEEM Study in The Lancet http://t.co/NGcqlw3s...
So far Altmetric has seen 0 pins from 0 accounts.
Altmetric can't track some types of mention - for example, radio or TV appearances - and occasionally we'll miss blogs or news mentions. This tab contains data that we've manually added to the article's record.
Score in context
Puts article in the top 5% of all articles ranked by attention
show more...
Mentioned by
28 tweeters
1 Facebook users
1 F1000 reviews
1 news outlets
1 science blogs
Readers on
13 Mendeley
0 CiteULike
Track this article